The most abundant cannabinoid in hemp oil, making up over 90% of the cannabinoid content, cannabidiol or CBD is non-psychoactive and is the focus of the benefits from hemp oil. CBD has little affinity for CB1 or CB2 receptors, the main points of interaction for cannabinoids in the endocannabinoid system, and instead acts as an indirect antagonist of cannabinoid agonists, possibly allowing CBD to temper the high caused by THC. Our Gold Label RSHO™ is almost 25% CBD, making up most of oil’s weight. All other cannabinoids come in under 0.4% by weight.
Success stories like Oliver’s are everywhere, but there’s not a lot of data to back up those results. That’s because CBD comes from cannabis and, like nearly all other parts of the plant, is categorized by the Drug Enforcement Agency (DEA) as a Schedule 1 drug—the most restrictive classification. (Others on that list: heroin, Ecstasy, and peyote.) This classification, which cannabis advocates have tried for years to change, keeps cannabis-derived products, including CBD, from being properly studied in the U.S.
Our commitment to product quality and purity has driven HempMeds® to develop the strictest testing process in our industry, the Triple Lab Tested™ standard. We use ISO/IEC 17025:2005 accredited testing labs to examine our hemp oil and assure both its safety and consistency. These labs test our hemp oil for the concentration of cannabinoids, including CBD, CBDa, CBG, THC, and over a half dozen others. By testing our hemp oil three times during our process, we ensure that our products are completely safe for use by you and your entire family.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160